Xeris Biopharma (NASDAQ:XERS) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Xeris Biopharma has been given a Sell (D-) rating by Weiss Ratings, highlighting concerns about the company's stock performance.
• Despite the negative rating from Weiss, Zacks Research and Wall Street Zen recently upgraded their ratings to a Strong Buy, indicating mixed analyst opinions on the stock.
• The company reported a revenue of $67.71 million for the last quarter, surpassing analyst expectations, which added to the complexity of its investment outlook.

Xeris Biopharma (NASDAQ:XERS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

A number of other research firms have also recently commented on XERS. Zacks Research raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 13th. Wall Street Zen raised shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 18th. HC Wainwright assumed coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Leerink Partners upped their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.08.

Xeris Biopharma Trading Up 0.9%

NASDAQ XERS traded up $0.09 during trading hours on Friday, reaching $9.22. The company had a trading volume of 1,295,222 shares, compared to its average volume of 2,468,778. The stock has a 50-day moving average of $8.05 and a 200 day moving average of $5.97. Xeris Biopharma has a 1-year low of $2.82 and a 1-year high of $9.48. The stock has a market capitalization of $1.49 billion, a P/E ratio of -43.88 and a beta of 0.39.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million. As a group, sell-side analysts predict that Xeris Biopharma will post -0.41 EPS for the current year.

Insider Buying and Selling

In related news, Director John Johnson sold 107,500 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the completion of the sale, the director directly owned 833,483 shares of the company's stock, valued at $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Sherman sold 42,232 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $7.92, for a total value of $334,477.44. Following the sale, the director directly owned 219,188 shares of the company's stock, valued at approximately $1,735,968.96. This represents a 16.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 207,732 shares of company stock valued at $1,550,437 in the last ninety days. Company insiders own 6.47% of the company's stock.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds have recently modified their holdings of XERS. Xponance Inc. acquired a new stake in Xeris Biopharma in the first quarter valued at $57,000. FORA Capital LLC purchased a new stake in Xeris Biopharma during the 1st quarter worth about $60,000. State of Alaska Department of Revenue purchased a new stake in Xeris Biopharma during the 3rd quarter worth about $68,000. Tower Research Capital LLC TRC increased its position in Xeris Biopharma by 913.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company's stock worth $81,000 after purchasing an additional 15,678 shares in the last quarter. Finally, Modern Wealth Management LLC purchased a new stake in Xeris Biopharma in the 2nd quarter valued at about $83,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.